CHLOROFORM Compound
Chloroform (CAS # 67-66-3) is a colorless liquid at room temperature. The chemical name is trichloromethane and its molecular formula is CHCl3 with a molecular weight of 119.39. It is available from Aldrich (Miwaukee, WI).
Mode of Action
Chloroform is generally believed to produce its toxic and carcinogenic effects through the cytotoxic action of one or more of its metabolites. Sustained cytotoxicity leads to regenerative cell proliferation and to carcinogenic responses in tissues where the metabolites are formed.
Rationale for Selection
Chloroform ts the de nition of a classic nongenotoxic carcinogen. It is, therefore, an ideal candidate chemical for evaluating the utility of the transgenic mouse models and their response to tumor promoting events, such as cytotoxicity and regenerative cell proliferation.
Rodent Carcinogenicity
There is an extensive database on the toxicology of chloroform as reviewed in the document prepared by the Agency for Toxic Substances and Disease Registry (1) . Depending upon the method of administration, chloroform was shown to be tumorigenic to rats and mice in the liver or kidney. Chloroform, when administered in corn oil by oral gavage, has been shown to increase the incidence of hepatocellular carcinomas in male and female mice (2) . In the National Cancer Institute (NCI) bioassay, the average doses administered were 138 and 277 mg/kg for males and 238 and 477 mg/kg for females. The incidence of hepatocellular carcinomas was 98% and 95%, for males and females respectively at the high dose, and 36% and 80% for males and females at the low dose, respectively. Under the conditions of the NCI study where tumors were 323 0192-6233/01$3.00 $0.00
Metabolism
Chlorpromazine has been reported to be metabolized in humans to 7-hydroxy-chlorpromazine, chlorpromazine sulfoxide, norchlorpromazine, and dinorchlorpromazine.
Analytical Methods
Information on the analytical methods for CPZ in formulations may be found in the European Pharmacopeia. For toxicokinetic evaluation, analytical methods for chlorpromazine in plasma have been described using HPLC or GC-MS equipment (1, 2) .
Rodent Carcinogenicity
Chlorpromazine has been classi ed as a rodent carcinogen. It has induced pancreatic tumors in male rats but not female rats or male or female mice. Due to its prolactin stimulation properties it has been suggested that CPZ possesses the potential to induce mammary tumors (3) .
Genotoxicity
Chlorpromazine is negative in most standard genotoxicity tests conducted. However, there are some reports that it has been found to be positive in the Ames-test with metabolic activation. In combination with UV irradiation CPZ has been shown to be genotoxic in a number of test-systems (4) .
Epidemiology
There is no evidence of association between chronic dosing and mammary tumorigenesis, but epidemiologic data are limited. 
CLOFIBRATE Compound
Clo brate (ethyl-alphap-chlorophenoxyisobutyrate, CAS 637-07-0, C 12 H 15 O 3 Cl) has a molecular weight of 242.7, a boiling point of 148-150 C at 25 mm Hg, and a speci c gravity of 1.138-1.144 at 20 C. Clo brate is a colorless to pale yellow liquid with a faint characteristic odor and taste. Clo brate is insoluble in water and soluble in alcohol and chloroform.
Pharmacological Activity
Clo brate is a hypolipidemic agent which lowers lipids by an unknown mechanism. Several mechanisms of action have been proposed for the pharmacological effect of Clo brate that may induce an increase in lipoprotein lipase activity, which results in a reduction of very low and intermediate density lipoproteins (VLDL, IDL) that are rich in triglycerides. Inhibition of hepatic synthesis and release of lipoproteins (particularly VLDL) or an increase in the fecal excretion of neutral sterols may also contribute to clo brate's antilipidemic activity.
Rationale
Clo brate was selected as an example of a rodent liver carcinogen which, based on epidemiologic evidence, does not appear to be a human carcinogen. Clo brate induces hepatic carcinoma in susceptible species. Rats and mice are susceptible to clo brate-induced hepatocarcinogenesis, hamsters are partially responsive; guinea pigs, marmoset, Rhesus monkeys, and man are nonresponsive. Clo brate is not genotoxic and functions as a tumor promoter in the two stage model of carcinogenesis. Clo brate has been studied extensively and issued as a prototypical drug which induces peroxisomal proliferation and carcinogenesis in rodents. A strong correlation between peroxisomal proliferation and hepatocarcinogensis in rodents has been established, however, it is unclear what role peroxisomal proliferation has in neoplasm development. Proposed mechanisms for clo brate-induced carcinogenicity include induction of sustained oxidative stress, enhanced cell replication, and promotion of spontaneous preneoplastic lesions.
Rodent Carcinogenicity
Clo brate-induces dose dependant hepatocellular carcinomas in rats and mice. Morphological changes in the liver include cellular hypertrophy and hyperplasia, and these most likely contribute to the characteristic liver enlargement observed after clo brate treatment. Clo brate induced carcinogenesis is mediated by a nongenotoxic mechanism. Clo brate is considered to be a tumor promoter but the promoting ability of clo brate is dependent on the initiator used.
Genotoxicity
Clo brate is considered to be nonmutagenic. Clo brate does not bind to DNA when administered in vivo and no binding to DNA can be detected by 32 P-postlabelling. Clobrate is completely negative in in vivo tests of genotoxicity and mainly negative in in vitro analyses of genotoxicity. In vivo analyses of sister chromatid exchange using rat blood lymphocytes and Chinese hamster bone marrow were negative. Similarly, an in vivo study of chromosome aberrations in rat bone marrow was also negative. Clo brate was negative in the Ames test ( S9) and the Bacillus subtilis recombination assay and point mutations were not detectable in V79 Chinese hamster lung cells ( S9) at the hypoxanthine guanine phosphoribosyl transferase (HGPRT) locus. A slight, dose-independent increase in sister chromatid exchange was observed in Chinese hamster ovary cells ( S9). In Chinese hamster lung cells positive chromosomal aberrations have been reported without S9. Likewise, measurement of cell transformation in Syrian hamster embryo cells gave positive results in the absence of S9.
Epidemiology
An epidemiology study sponsored by the World Health Organization examined the carcinogenic effect of clo brate in 15,745 humans. The data indicate that clo brate treatment did not result in a increase in tumor incidence when compared to the control group. Clo brate has been administered extensively to humans and clo brate is not considered to be a human carcinogen. 
Reviews/Monographs

CYCLOPHOSPHAMIDE
Compound
Cyclophosphamide monohydrate (CAS # 6055-19-2) is 2H-1,3,2-oxazaphosphorin-2-amine, N,Nbis(2-chloroethyl) tetrahydro-, 2-oxide, monohydrate. It is a ne, white odorless crystalline powder, slightly bitter, with a molecular weight of 279.1. The compound is soluble in ethanol; the solubility in water is 40 mg/mL. It is available from Lancaster Synthesis (Windham, NJ).
Pharmacologic Activity
Cyclophosphamide is an antineoplastic, immunosuppressan.
Rationale
Cyclophosphamide was selected as a known human genotoxin and carcinogen. The compound has been widely used for more than 40 years, and the genotoxicity and carcinogenicity have been characterized in numerous studies. The compound is not cytotoxic per se, but is readily absorbed, converted to toxic metabolites, and excreted. Toxicity is marked by leucopenia in most species, and this change can serve as a marker of exposure (1) .
Rodent Carcinogenicity
Cyclophosphamide has been tested for carcinogenicity in rats and mice. In rats, lifetime treatment with cyclophosphamide in the drinking water caused an increased incidence of neoplasms of the hematopoietic system, neurogenic sarcomas, and transitional cell carcinomas of the urinary bladder.
In other studies with rats and mice, cyclophosphamide was administered parenterally and various tumor types were increased in incidence. Of particular importance is the observation that neoplasms have been induced in rodents by doses of cyclophosphamide that are lower (mg/kg basis) than human therapeutic doses (1) .
Genotoxicity
Cyclophosphamide has been shown to be genotoxic in numerous in vitro test systems and in vivo in experimental animals and humans. In in vitro systems, cyclophosphamide is genotoxic when tested with liver activation systems. These in vitro tests include point mutations in S. typhimurium and E. coli and mutagenesis and chromosomal aberrations in mammalian cells. Positive micronucleus tests, chromosomal aberration, and sister chromosome exchange in bone marrow, in vivo, have been shown in multiple rodent species. In humans, chromosomal aberrations and sister chromatid exchange have been shown in peripheral blood lymphocytes of cyclophosphamide-treated individuals (1) .
Epidemiology
A number of cases of malignancy have been reported in humans who have been treated with cyclophosphamide for malignancies or for nonmalignant disorders. Neoplasms associated with cyclophosphamide treatment include those of the urinary bladder and hematopoietic and lymphreticular systems. The epidemiologic evidence indicates that cyclophosphamide increases the incidence of urinary bladder tumors and may increase the incidence of other neoplasms (1).
CYCLOSPORIN A Compound
Cyclosporin A (CAS # 59865-13-3). The chemical name is (R-(R w , R w -, (E)))-Cyclic (L-alanyl-D-alanyl-N-methyl-Lleucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N, 4-dimethyl-L-2-amino-6-octenoyl-L -alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-Lleucyl). Its molecular weight is 1202.84. Cyclosporin A is characterized by white prismatic crystals from acetone. It is a neutral, hydrophobic, cyclic nonpolar oligopeptide composed of 11 amino acid residues and is insoluble in water and n-hexane, and very soluble in all organic solvents. The compound is available from Sandoz in bottles containing 100 mg/mL in an olive oil-based solution and 12.5% ethanol for oral administration, and in ampules containing 50 mg/mL with 33% ethanol and 650 mg polyoxethylated castor oil for intravenous injection.
Pharmacologic Activity
Cyclosporin is an immunosuppressive agent.
Rationale
Cyclosporin was selected as a human carcinogen acting through an immunosuppressant mode of action. Cyclosporin is used extensively in the prevention and treatment of graft vs host reactions in bone marrow transplantation, and for the prevention of rejection of kidney, heart, and liver transplants. It has also been tested for the therapy of a large variety of other disease in which immunological factors may have a pathogenic role, including Graves' disease, uveitis, Crohn's disease, ulcerative colitis, chronic active hepatitis, dermatomyositis, systematic lupus erythematosus, and psoriasis. Traditional rodent cancer studies have not been particularly informative with respect to the carcinogenicity of cyclosporin. The testing of cyclosporin in the transgenic mouse models will yield information on the utility of these models in identifying human cancer hazards that are: 1) not readily identi ed in standard rodent cancer bioassays, and 2) are thought to elicit cancer through mechanisms other than the direct alteration of DNA.
Human Carcinogenicity
Both lymphomas and Kaposi's sarcoma have been associated with exposure to cyclosporin. It has also been reported that organ transplant recipients have a higher incidence of lymphoma after treatment with cyclosporin either alone or in combination with other cytotoxic drugs. It is also documented that regression of lymphoma occurs following the withdrawal of the drug. The International Agency for Research on Cancer (IARC) classi es cyclosporin as having suf cient evidence of carcinogenicity in humans (1) .
Rodent Carcinogenicity
Cyclosporin A was tested for carcinogenicity by oral administration in two studies in mice and one study in rats. In one study of mice that are susceptible to the induction of leukemias, it accelerated the development of thymic lymphomas but in a chronic bioassay using male and female OF1 mice, no tumors were induced. In a study in rats the results were negative. IARC classi es cyclosporin A as having limited evidence for carcinogenicity in experimental animals.
Genotoxicity
Cyclosporin did not induce dominant lethal mutations in mice, chromosomal aberrations in the bone marrow of Chinese hamsters or micronuclei in the bone marrow of Chinese hamsters or mice in vivo. It induced sister chromatid exchange in human peripheral lymphocytes in vitro but did not induce gene mutations in Chinese hamster cells. Cyclosporin did not induce mutations in Salmonella typhimurium.
DI(2-ETHYLHEXYL) PHTHALATE Compound
The chemical formula of di(2-ethylhexyl) phthalate (CAS 117-81-7) is C 24 H 38 O 4 . Di(2-ethylhexyl) phthalate is used primarily as one of several plasticizers in polyvinyl chloride (PVC) resins for fabricating exible vinyl products such as the manufacture of medical devices. According to CPSC, EPA, and FDA, these PVC resins are used to manufacture many products, including teething rings, paci ers, soft squeeze toys, balls, vinyl upholstery, tablecloths, shower curtains, raincoats, adhesives, polymeric coatings, components of paper and paperboard, defoaming agents, enclosures for food containers, animal glue, surface lubricants, exible devices for administering parenteral solutions, and other products that must stay exible and noninjurious for the lifetime of their use. Di (2-ethylhexyl) phthalate also is used to manufacture vinyl gloves used for medical examinations and surgery (about 500 million pairs annually). The only signi cant nonplasticizer use for di (2-ethylhexyl) phthalate is as a replacement for polychlorinated biphenyls in dielectric uids for electric capacitors.
Di(2-ethylhexyl) phthalate is a colorless liquid with a slight odor. It is insoluble in water, miscible with mineral oil and hexane, and soluble in most organic solvents. Di(2ethylhexyl) phthalate is easily dissolved in body uids such as saliva and plasma. This chemical is stable under normal laboratory conditions and UV spectrophotometric stability screening indicates that solutions of this chemical in 95% ethanol are stable for at least 24 hours. This compound is incompatible with oxidizing materials, nitrates, strong acids, and strong alkalies.
Rationale
Di(2-ethylhexyl) phthalate was selected for inclusion in these studies because of its human exposure and because it is known as a rodent liver carcinogen, based on the results from the US National Toxicology Program two-year rodent carcinogenicity bioassay.
The primary routes of potential human exposure to di(2ethylhexyl) phthalate are inhalation, ingestion, and dermal contact. A substantial fraction of the United States population is exposed to measurable levels of DEHP. Total releases of DEHP to the environment in 1988 were 1.2 million pounds. A highly exposed segment of the population consists of individuals receiving dialysis treatments or large quantities of blood that have contacted di(2-ethylhexyl) phthalatecontaining tubing or containers. In addition, the National Occupational Exposure Survey (1981-1983) indicated that 147,848 workers, including 50,694 women, were potentially exposed to di(2-ethylhexyl) phthalate. This estimate was derived from observations of the actual use of the compound (4% of total observations) and the use of trade name products known to contain the compound (96%).
Rodent Carcinogenicity
There is suf cient evidence for the carcinogenicity of di(2ethylhexyl) phthalate in experimental animals. In feed studies conducted by the US National Toxicology Program, di(2ethylhexyl)phthalate was carcinogenic for F344/N rats and B6C3F 1 mice, causing increased incidences of hepatocellular carcinomas in female rats and male and female mice, and inducing an increased incidence of either hepatocellular carcinomas or neoplastic nodules in male rats.
Genotoxicity
Di(2-ethylhexyl) phthalate was not mutagenic to Salmonella typhimurium. However, it caused dominant lethal mutations in mice after systemic but not oral administration. It has been reported as being negative in mouse lymphoma, in the in vitro chromosome aberration and sister chromatid exchange tests in CHO cells and in the Drosophila melanogaster sex-linked recessive lethal and reciprocal translocations assays.
Epidemiology
An IARC Working Group reported there were no adequate data available to evaluate the carcinogenicity of di(2ethylhexyl) phthalate in humans but it has classi ed it as being in Group 2B: possibly carcinogenic to humans.
DIELDRIN
Compound
Dieldrin (CAS # 60-57-1), C 12 H 8 OCl 6 , molecular weight 380.93, is an organochlorine insecticide of the cyclodiene group, which includes aldrin, chlordane, heptachlor, isodrin, endrin, isobenzan, and a-endosulfan. Dieldrin may also be referred to as HEOD from the chemical name, which is 1,2, 3,4,10,10-hexachloro-6,7,-epoxy-1,4,4a,5,6,7,8,8 a-octahydro-endo-1,4-exo-5,8,-dimethanonaphthalene.
Pure dieldrin is a white, crystalline, odorless solid that melts at 176-177 C. It is slightly soluble in mineral oils, other aliphatic hydrocarbons and alcohols; moderately soluble in acetone and soluble in aromatic and halogenated solvents. The insecticidal properties of dieldrin were rst described in 1949. Dieldrin was used extensively worldwide and was especially effective for protection of wood and related products against termites. Annual worldwide production of dieldrin during the period of its greatest usage was roughly 10,000 tons. Dieldrin was removed from the U.S. market in 1974.
Mode of Action
Chlorinated hydrocarbon insecticides act by altering the electrophysiological and associated enzymatic properties of nerve cell membranes, causing a change in the kinetics of Na and K ion ow through the membrane. The action of dieldrin is on the central nervous system.
Rationale
Dieldrin was selected as an example of a rodent carcinogen/putative human noncarcinogen based on epidemiology. The carcinogenic potential of dieldrin for rodents has been tested extensively by dietary administration in conventionally designed rodent bioassays with several strains of mice and rats. Tumor development was limited to the mouse liver. Dieldrin was also negative for tumor development in chronic dietary studies with hamsters, dogs and rhesus monkeys.
Human exposures in occupational settings were such that exposures could be reasonably de ned and long-term epidemiologic investigations were undertaken. No evidence of dieldrin having carcinogenic potential for humans has been discovered.
Rodent Carcinogenicity
The strains of mice and rats used for carcinogenicity bioassays of dieldrin are C3HeB/Fe, CF1, LACG, hybrid CF1-LACG, CD1, B6C3F1, C57Bl6J, C3H/He and C57Bl6J x C3H/He B6C3F1 hybrids and Sprague-Dawley, Carworth, Osborne-Mendel and Fischer 344, respectively. The dose levels of dieldrin, which can be tested chronically, are limited by its fatal toxicity at 10-20 mg/kg in diet (for mice these dietary levels are roughly equivalent to 1.5-3.0 mg/kg body weight). From the results of these bioassays dieldrin is considered to be a mouse liver carcinogen, with male mice generally more susceptible than female mice. Dieldrin induces increased liver weight, centrilobular hypertrophy and induction of P450 microsomal enzymes in mice and rats. Investigators have hypothesized that mice may be under a normally higher level of oxidative stress than the rat and thus mouseonly hepatocarcinogens such as dieldrin may upset the usual oxidant/antioxidant balance in the mouse liver leading to activation of oncogenes.
Genotoxicity
Dieldrin is not genotoxic. It has been tested extensively in a wide array of tests.
Epidemiology
A comprehensive report of a study of exposure, health effects and mortality of workers engaged in the manufacture and formulation of the insecticides aldrin and dieldrin was published by de Jong in 1991 (1) . The study covered the period from start of production (1954/1955) until cessation (1990) at the Shell facility at Pernis (near Rotterdam), The Netherlands with a total cohort of 570. No indications for increased cancer from exposure to dieldrin were uncovered (exposure histories were de ned by routine blood analyses). A study of the second Shell facility in Colorado (2) included 2,384 employees of all job classi cations. Potential exposures were not limited to aldrin and dieldrin and because a blood monitoring program was not conducted, exposures had to be estimated by job type. Although an excess of biliary duct/gall bladder cancer occurred in white men in hourly jobs, the authors concluded, for several reasons discussed in their report, that the excess was unlikely to have resulted from occupational exposures.
DIETHYLSTILBESTROL
Compound and Rationale
Diethylstilbestrol (DES, CAS # 56-53-1) is a synthetic estrogen. The chemical name is (E)-4,4 -(1,2-diethyl-1,2ethenediyl)bisphenol and it has molecular weight of 268.34. It is soluble in alcohol, ether, chloroform, and fatty oils, but nearly insoluble in water. The source of DES is Sigma, catalog # D-4628. Lot # 106H0643 is recommended. The certi cate of analysis from Sigma indicates a purity of 99.6%.
Pharmacologic Activity Estrogenic
Rationale DES was selected as a representative of a nonmutagenic (i.e., Ames/Salmonella negative) carcinogen acting through a receptor-mediated (estrogenic) mechanism.
Rodent Carcinogenicity
DES (500 or 1000 ppb) induces mammary carcinomas in both male and female mice (C3H) within 40 weeks (1) . Uterine adenosis (45%) and ovarian tubular adenomas (13%) have also been observed after feeding C3H MMTV substrains a diet containing 500 ppb DES within 26 and 78 weeks, respectively. Within this same study mice developed mammary hyperplastic alveolar nodules by 91 weeks (2) .
Genotoxicity
DES is nonmutagenic when tested in the bacterial reversion assay. (For a review, see 3). A number of in vitro studies using mammalian cells have been conducted. In vitro, DES has been shown to reproducibly induce aneuploidy. DES has also been shown to induce morphological transformation in SHE cells. In vivo, in addition to aneuploidy, DES has been shown to induce unscheduled DNA synthesis and DNA adducts. While several mechanisms for these effects have been proposed, including receptor-mediated effects, disruption of the mitotic apparatus, and the formation of a genotoxic metabolite, the exact mechanisms remain unclear.
Epidemiology
DES is classi ed by IARC as a Class I carcinogen (4) . This is primarily based on the evidence that DES is induces vaginal and cervical tumors in women exposed in utero. In addition, women treated with DES also exhibit an increased risk for development of breast cancer. The relative risk from several studies ranged from about 1.3 to 1.7. The long lag period between exposure and tumors, in addition to other evidence, has led to suggestions that the carcinogenicity is not due to direct DNA damage. However, the exact mechanisms accounting for these various responses are not clearly understood.
Dose Selection
Studies were initiated in p53 transgenic mice using doses of 500 and 1000 ppb in the feed. After about 2 months several males developed urinary bladder distention and hydronephrosis causing moribundity. The dose for the males was lowered to 50 and 250 ppb. No similar toxicity was seen in females. Therefore, based on this study, 500 ppb is thought to exceed the MTD in these male mice when dosing begins at 6-8 weeks of age. Subsequent 4 week range nder studies conducted in other labs in other transgenic models have suggested that 500 ppb may not exceed the MTD.
D-MANNITOL Compound
D-Mannitol (CAS # 69-65-8), C 6 H 14 O 6 , molecular weight 182.2, is an odorless white crystalline powder used in a wide variety of food processing applications, as a avor carrier or enhancer and as an osmotic diuretic. The FDA categorizes mannitol as generally regarded as safe (GRAS).
Rationale
D-mannitol was selected as an example of the category noncarcinogen based on results of rodent carcinogenicity bioassays and its accepted use in foods and products for human consumption.
Rodent Carcinogenicity
D-mannitol was tested by the National Toxicology Program in F344 rats and B6C3F1 mice at dietary levels of 2.5% and 5%. Tumor incidences were not increased after dosing for 103 weeks. Mannitol was included as a comparative control substance in a Wistar rat carcinogenicity study of erythritol. In this study mannitol was 10% of the diet and was offered for 104-107 weeks. The incidence of neoplastic lesions was not affected by the dietary mannitol.
Genotoxicity
D-mannitol was not genotoxic in bacterial mutagenicity assays.
17-b -ESTRADIOL Compound
17-b -Estradiol (CAS # 50-28-2). The chemical name is (17b)-estra-1,3,5(10)-triene-3,17-diol. C 18 H 24 O 2 . Its molecular weight is 272.4. It has white or creamy-white prisms and is practically insoluble in water. It is soluble in ethanol, acetone, chloroform, and diethyl ether. The compound is available from Sigma Chemical Co (St. Louis MO).
Pharmacological Activity
Estrogenic hormone therapy Rationale 17-b -Estradiol is the most active naturally occurring estrogenic hormone. Other than its natural production, humans are potentially exposed when consuming products from treated livestock, when used as a pharmaceutical agent, or through occupational exposures. The primary routes of potential human exposure are ingestion, injection, inhalation, and dermal contact. While not a point mutagen, chromosomal alterations have been reported both in vitro and in vivo. There is evidence for the carcinogenicity of 17-b-estradiol in rodents, targeting the estrogen responsive organs. Although no evidence exists for the carcinogenicity of 17-b -estradiol in humans, studies strongly suggest that administration of estrogens is associated with an increased incidence of endometrial carcinoma in humans.
Rodent Carcinogenicity
There is suf cient evidence for the carcinogenicity of 17-b-estradiol in experimental animals. When administered orally, the compound induced increased incidences of adenocarcinomas of the mammary gland, cervix, and uterus, adenoacanthoma of the uterus, and osteosarcoma of the cranium in female mice. Subcutaneous or intramuscular injection induced increased incidences of lymphosarcomas in mice of both sexes. Subcutaneous implants of 17-b -estradiol induced mammary tumors, including adenocarcinomas, papillary carcinomas, and anaplastic carcinomas in adult and newborn male and female mice and in female rats; pituitary chromophobe adenomas in male rats; bromyomas of the uterus, mesentery, and abdomen in female guinea pigs; and malignant renal tumors in hamsters of both sexes.
Genotoxicity
17-b-Estradiol has been shown to be inactive in point mutation assays including the Ames test and mammalian cell mutagenicity assays using Chinese hamster V79 cells or Syrian hamster embryo cells. In addition, the estrogen has not been shown to induce sister chromatid exchanges (SCEs) in cultured mammalian cells. Both negative and positive ndings have been reported for 17b-estradiol from in vitro assays for structural chromosomal effects. Aneuploidy (numerical chromosome changes) and morphological transformation have been reported in Syrian hamster embryo cells. In addition, the hormone has been shown to induce C-mitoses, polyploidies, and micronuclei in human lymphocytes in vitro, interpreted as resulting from errors in the anaphase distribution of chromosomes by spindle disturbances rather than from structural chromosomal aberrations.
Epidemiology
There is inadequate evidence for the carcinogenicity of 17-b-estradiol in humans. However, studies strongly suggest that administration of estrogens is associated with an increased incidence of endometrial carcinoma in humans, and there is no evidence that 17-b -estradiol is different from other estrogens in this respect. An IARC working group concluded that in the absence of adequate data on humans, it is reasonable to regard 17-b -estradiol as if it presented a carcinogenic risk to humans. Haloperidol is a faint yellow, colorless, tasteless, microcrystalline or amorphous powder prepared by chemical synthesis. The compound can be ordered at Janssen Pharmaceutica (batch no. ZR00126; compound coordinator Koen Van Deun).
Reviews/Monographs
Pharmacological Activity
Haloperidol is a potent antagonist of central and peripheral dopamine receptors, and is partially selective for the D 2 -receptor. The binding to D 2 receptors, particularly in the corpus striatum brings about the main pharmacological effects of haloperidol and produces a temporary rise in dopamine metabolite concentrations in the CSF. By antagonizing dopamine receptors in the chemoreceptor trigger zone, haloperidol is an effective antiemetic. Haloperidol has potent antagonist activity at the central r -opiate receptors and has weak antagonist activity at muscarinic cholinergic receptors, histamine (H 1 ) receptors, adrenergic receptors, and serotonin receptors (5HT 1A and 5HT 2 ).
Rationale
Haloperidol was chosen as an example of a receptor active compound which produces a carcinogenic effect in mice related to increased prolactin release mediated through dopamine receptor antagonism. Based on its mechanism and extensive clinical experience, haloperidol does not appear to be a human carcinogen, although direct epidemiologic evidence is limited.
Toxicology and Genetoxicity
A review of the literature reveals no haematological, ocular, renal, hepatic, or electrolytic toxicity. There have been reports of a weak leukaemogenic action in mice, but this does not seem to be of signi cance in man. No other mutagenic actions have been reported. The drug produces an increase in serum prolactin which is of clinical signi cance (see adverse reactions below). It has also been reported to elevate transiently the erythrocyte sedimentation rate and AST but this does not have any adverse clinical signi cance and returns to normal after 4 months.
Carcinogenicity Studies
Long-term carcinogenicity study in CD1 Swiss mice, in an 18-month carcinogenicity study with haloperidol in the albino Swiss CD1 strain (Experiment No. 1082, completed 1984, Janssen Research Foundation), dose levels were 0.16, 0.63 and 2.5 mg/100 food, corresponding with intended dosage levels of 0.31, 1.25 and 5 mg/kg body weight/day. Parameters studied were survival, clinical observations, gross pathology, and histopathology.
There were no drug-or dose-related effects on mortality. Clinical observations were comparable between controls and 0.16 mg/100 g dosed mice. At 0.63 and 2.5 mg/100 g food the incidence of subcutaneous tissue mass was increased in females. Sedation was seen in males and females dosed at 2.5 mg/100 g food. Comparable gross pathological ndings were seen between controls and male mice of all dosage groups and female mice of 0.16 mg/100 g food. A drug and dose-related increase in mammary gland stimulation and tissue masses and of swollen hypophysis often accompanied with haemorrhagic changes was seen in females dosed at 0.63 and 2.5 mg/100 g food. No drug-related, nonneoplastic, or neoplastic histological changes were seen in males of all dosage groups or in females dosed at 0.16 mg/100 g food. In the female dosage groups of 0.63 and 2.5 mg/100 g food, the following incidences were increased in a dose-dependant manner: pituitary gland hyperplasia and ademona as well as mammary gland hyperplasia and metaplasia and (adeno)carcinoma.
Whereas pituitary ademonas were mostly incidental ndings, mammary gland carcinomas were often fatal. The mechanism of these effects was explained by the dopamineantagonism of haloperidol resulting in enhanced prolactin release. The latter property results in chronic tissue stimulation of both the pituitary and mammary glands. Besides hyperand/metaplasia, the oncogenic endpoints of this stimulation were adenoma of the pituitary gland or carcinoma of the mammary gland in the genetically sensitive mouse species. Furthermore, it is known that these prolactin effects in rodents are produced by a variety of neuroleptic drugs but the relevance to man is questionable. Finally, it was concluded that, besides the prolactin-mediated effects, haloperidol was not evidenced to possess a genotoxic carcinogenic potential which was further con rmed by the results of the mutagenicity studies.
Dose-Range-Finding Study in Wild-Type Mice
Based on the above assumptions, it was concluded that the dose of 0.16 and 5 mg/100 g food would be appropriate for the low and high doses for the 6-month short-term carcinogenicity in rasH 2 mice, corresponding to 0.31 and 10 mg/kg body weight (below and above threshold for prolactin-mediated promoting effects, respectively).
MELPHALAN
Compound
The chemical formula for melphalan (CAS # 148-82-3) is C 13 H 18 Cl 2 N 2 O 2 . It is a derivative of nitrogen mustard that is used as an antineoplastic agent. It has a molecular weight of 305.2 and is a white to buff-colored, odorless powder that is practically insoluble in water but is subject to rapid hydrolysis in water and plasma. It is sensitive to light. Stability increases in acidic solutions. It has been shown to have a solubility of < 1 mg/mL @ 22 C in water, DMSO, 95% ethanol, and acetone. Solutions in isotonic saline have a half-life of 12.5 hours at 20 C and a half-life of 1.8 hours at 37 C. In a 0.001M NaCl solution (10 l g/mL), complete hydrolysis at 37 C takes place in 3 hours. It has been shown to be stable in solutions of DMSO at 20 C for over a month even with frequent thawing. NMR spectrophotometric stability screening indicates that solutions of this compound in DMSO are stable for at least 24 hours. Solutions in methanol were found to retain full integrity for >12 hours at room temperature and for at least 4 weeks at 20 C. When heated to decomposition, it emits toxic fumes of hydrochloric acid and other chlorinated compounds as well as nitrogen oxides (NO X ). Melphalan U.S.P.-grade powder, used to formulate tablets, contains 93.0-100.5% melphalan.
Melphalan is not currently produced in the United States, and only one domestic supplier has been reported. The USITC reports that 1983 imports of melphalan totaled 363 lbs, compared with an estimated 3,000 lbs. imported in 1977.
Rationale
Melphalan is an alkylating agent of the nitrogen mustard type. Melphalan is a bifunctional alkylating agent and is cell cycle-phase nonspeci c. Activity occurs as a result of formation of an unstable ethylenimmonium ion, which alkylates or binds with many intracellular molecular structures including nucleic acids. Its cytotoxic action is primarily due to cross linking of strands of DNA and RNA, as well as inhibition of protein synthesis.
Melphalan was selected for inclusion in these studies because it was positive in the Salmonella assay, the 2-year rodent bioassay conducted by the National Toxicology Program, and is classi ed as an IARC Group 1 human carcinogen.
The primary routes of potential human exposure to melphalan are ingestion or injection during the treatment of multiple myeloma and cancer of the ovary or in investigations of other types of cancer. Health professionals (e.g., pharmacists, nurses, and physicians) involved in cancer chemotherapy may be exposed to melphalan during drug preparation, administration, or clean up. Potential occupational exposure via inhalation or dermal contact may also occur for workers involved in the formulation and packaging of the pharmaceuticals.
Rodent Carcinogenicity
There is suf cient evidence for the carcinogenicity of melphalan in experimental animals. When administered by intraperitoneal injection, melphalan induced lymphosarcomas in male mice, lung tumors in mice of both sexes, and peritoneal sarcomas in rats of both sexes.
Genotoxicity
Melphalan was evaluated by the EPA GENETOX Program in 1988 and the results for D. melanogasterreciprocal translocation, and E. coli polA without S9 were considered to be inconclusive. The results for in vitro SCE-nonhuman; C3H/10T1/2 Cell transformation; D. melanogaster sex-linked lethal; histidine reversion-Ames test; in vitro cytogenetics-human; E. coli polA with S9; in vitro cytogenetics-nonhuman; and in vitro SCE-human lymphocytes were considered to be positive.
Epidemiology
An IARC working group has reported that there is sufcient evidence for the carcinogenicity of melphalan in humans. Epidemiological studies showed substantially increased rates of leukemia in patients treated with melphalan for breast cancer, ovarian cancer, and multiple myeloma. 4 
Pharmacologic Activity
Metaproterenol is a ß2 adrenergic agonist with an intermediate duration of action (3-6 hours). The primary therapeutic use is as a bronchodilator in patients with bronchial asthma, both for the relief of acute symptoms and the prevention of exercise-induced bronchospasm (1) .
Rationale
A ß2 adrenergic agonist was chosen for testing because of speci c action in rodent carcinogenicity models. Metaproterenol is not genotoxic and has not been associated with neoplasia in humans.
Rodent Carcinogenicity
ß adrenergic agonists as a class have been associated with the development of leiomyomas in female rodents (1) (2) (3) (4) . Treatment of female rats causes development of leiomyomas in the ovarian suspensory ligament (costo-uterine smooth muscle). The development of leiomyomas by ß agonists is due to excessive stimulation of a tissue with ß2 receptors, is directly related to the pharmacologic potency, and can be inhibited by ß-blockade.
Metaproterenol was tested for carcinogenicity in rats and mice administered metaproterenol in the diet (5) . In rats, treatment with metaproterenol for 2 years was associated with a nonsigni cant increase in leiomyomas of the mesovarium in female rats given 100 mg/kg/day. In a 78-week carcinogenicity study in NMRI mice, increased incidences of benign hepatic adenomas in males and benign ovarian tumors in females were associated with doses of 50 and 100 mg/kg/day (6) .
Genotoxicity
Genotoxicity tests were conducted or contracted by Lilly Research Laboratories. In these tests, metaproterenol was not mutagenic in the Ames S. typhimurium/E. coli bacterial mutation assay, with and without metabolic activation (1), nor in the L5178 TK / mouse lymphoma forward mutation assay, with and without metabolic activation (8) . Metaproterenol did not induce chromosomal aberrations in Chinese hamster ovary cells, with and without exogenous metabolic activation (9), and did not induce micronuclei, in vivo, in bone marrow of ICR mice (10) .
Epidemiology
A number of ß agonists, including metaproterenol, have been in clinical use as bronchodilators for a number of years. There has been no evidence of increased incidence of leiomyomas in humans associated with this clinical use.
METHAPYRILENE HYDROCHLORIDE Compound
Methapyrilene hydrochloride (CAS N 135-23-9). The formula is C 14 ClH 19 N 3 S.HCl and the chemical name usually used is N,N dimethyl-N -2-pyridinyl-N -(2-thienylmethyl)-1,2-ethanediamine monohydrochloride. Its molecular weight is 297.85. It appears as a white crystalline powder. About 100 mg of the chemical dissolves in 1 mL of water or in 95% ethanol at 20.5 C (1 g dissolves in 5 ml of alcohol), such solutions should be stable for 24 hours under normal laboratory conditions. This chemical is light sensitive and is available from Sigma-Aldrich Chimie (Saint Quentin Fallavier, France (25g-107 FF)).
Pharmacological Activity
Antihistamine (H1 receptor antagonist)
Rationale
Methapyrilene hydrochloride has been widely used in a variety of over-the-counter sleep aids and cold and allergy medications during the 1970s. It was withdrawn from the market following the report of its hepatocarcinogenic potential in the rat. Further studies in the rat con rmed that the chemical administered in the food or in drinking water induced a dose-dependent increase of cholangiocellular and hepatocellular carcinomas. The chemical was reported to be negative in most genetic toxicology assays, although there are con icting results. The mechanism for the carcinogenic effect remains unclear (complete carcinogen, promoter, syncarcinogen, or cocarcinogen), This compound was selected as a receptor active hepatocarcinogen, with potentially limited relevance for potential risk to man, on the basis of comparative experimental studies between man and rodents.
Rodent Carcinogenicity
Methapyrilene hydrochloride tested by chronic feeding in rats for two years at doses of up to 1,000 ppm, gave an incidence of 100% for liver tumors (hepatocellular and cholangiocellular carcinoma) after 43-64 weeks of treatment. This carcinogenic potential in the rat liver was con rmed in other studies in the food or in the drinking water. A full two-year carcinogenic study has not been performed in the mouse. However, in investigative studies, no hepatocarcinogenic effect was reported in Syrian golden hamster, guinea pig, and B6C3F1 mouse at equivalent dose-levels to those used in the rat. Positive effects have been seen on S-phase synthesis in the rat, and the chemical has been shown to enhance the carcinogenicity of two genotoxic carcinogens (N-2 uorenylacetamide and nitrosodiethylamine) in the rat by a syncarcinogenic or cocarcinogenic effect.
Genotoxicity
Numerous short-term tests for genotoxicity have been conducted. Con icting results were reported concerning the Ames test, DNA adducts, and mouse lymhoma assay. The chemical is negative for sister chromatid exchange in vivo and in vitro, also for unscheduled DNA sythesis in vivo and in vitro in rat and mouse, and in hepatocyte-mediated Chinese hamster ovary/hypoxanthine-guanine phosphoribosyl transferase assay. The chemical was positive in chromosomal aberration studies (mouse lymphoma assay, CHO-K1-BH4 cells), and in the in vitro micronucleus assay (hamster lung V7 cells). It was suggested that the chemical acts by an indirect genotoxic mechanism such as DNA intercalation, oxidative damage, aberrant DNA methylation, interaction with enzymes, or chromosomal structural proteins.
Epidemiology
In humans, this chemical was reported to be toxic by ingestion (gastritis, nervous disorders, renal necrosis), although no epidemiologic studies are available.
PHENACETIN
Compound
Phenacetin is a drug with analgesic and antipyretic propreties. Commercial analgesic preparations combined phenacetin and caffeine with either aspirin or phenazone. Phenacetin nephritis, or more accurately analgesic abuse-associated nephropathy, was rst described in 1953 (1) and was characterized by chronic, nonpurulent interstitial nephritis and renal papillary necrosis. The rst report linking carcinoma of the renal pelvis to analgesic abuse was published in 1965 (2) . Metabolic pathways common to phenacetin and aromatic amines, known bladder carcinogens, implicated phenacetin as the carcinogenic agent in the analgesic formulations.
Rationale
Phenacetin has been chosen as an example of a rodent and human carcinogen.
Rodent Carcinogenicity
Experimental evidence for the carcinogenicity of phenacetin is controversial. Although urothelial cell hyperplasia was a common nding in most rodent bioassays, early studies failed to demonstrate tumors when phenacetin was administered singly (3) (4) (5) or in combination with aspirin and caffeine (5, 6) . Later studies, which tended to be of longer duration, detected phenacetin-induced tumors in both rats and mice (7) (8) (9) (10) . Interestingly, positive responses in the rodent bioassays were not restricted to urinary tract neoplasms, but also included tumors of the lung, liver, mammary gland, nasal cavity and ear duct.
Based on experimental evidence, phenacetin is reasonably expected to be a human carcinogen and has been classi ed as a group 2A carcinogen by the International Agency for Research on Cancer and a group B2 chemical by the Environmental Protection Agency.
Genotoxicity and Tumor Promotion Activity
The mechanism by which phenacetin exerts its carcinogenic effect is not well de ned. Experimental evidence supports both a direct role as a genotoxic carcinogen and an indirect role as a tumor promoter. Phenacetin was positive in the Ames reversion assay using hamster liver S9, but not rat liver S9 (11, 12) , and induced chromosome aberrations in vitro when incubated in the presence of a rat liver metabolic activation system (13) . Alternatively, phenacetin has been shown to act as a promoter using either N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (14) or N-nitrobutyl-N-(4hyroxybutyl )amine (15) as initiators. Phenacetin increased the labeling index of bladder and kidney urothelium (16) and nasal olfactory epithelium (17) as would be expected for a tumor promoter.
RESERPINE
Compound
Reserpine (CAS # 50-55-5)
Pharmacological Activity Antihypertensive
Rationale
Reserpine is carcinogenic in male rats and male and female mice. There is no epidemiological evidence that it poses a carcinogenic risk to humans. Reserpine is nongenotoxic in a variety of in vitro tests, but is positive in the SHE cell transformation assay.
Rodent Carcinogenicity
The reserpine carcinogenicity bioassays were performed by the National Cancer Institute/National Toxicological Program and the report of the bioassays was released in 1980 (National Cancer Institute, Carcinogenesis, Technical Report Series, No. 193, . These studies were performed according to current bioassay performance standards. The duration of these studies was two years; the bioassays were conducted in both sexes in two species (F344 rats and B6C3F1 mice), with 50 animals/sex/dose group and two dose groups plus a vehicle-treated control group. The results of these bioassays demonstrated test agent-related increases in three different neoplasias, including adrenal medullary phechromocytomas in male rats, undifferented carcinomas of the seminal vesicle in male mice, and mammary cancer in female mice.
Genotoxicity and Cell Transformation
Reserpine produces negative results with and without metabolic activation in genotoxicity tests for gene mutation in Salmonella, for chromosome aberrations in chinese hamster cells and human cells, for sister chromatoid exchange in human cells and for unscheduled DNA synthesis in rat primary hepatocytes (1) . Reserpine was positive in both the standard and reduced pH versions of the Syrian Hamster Cell Transformation assay (2) .
Epidemiology
Multiple epidemiological studies do not show a consistent increase in risk of human cancer associated with exposure to reserpine (3, 4) .
SODIUM PHENOBARBITAL Compound
Sodium phenobarbital (CAS # 57-33-0). The chemical name is 5-ethyl-phenyl-2,4,6 (1H,3H,5H) pyrimidinetrione monosodium salt. Its molecular weight is 254.22. Bitter slightly hygroscopic crystals or powder. One gm of phenobarbital dissolves in about 1 ml of water or 10 ml alcohol. The compound is available from Sigma Chemical Co. (St. Louis, MO; 100g-96; 500g-382).
Pharmacological Activity
Sedative/hypnotic, anticonvulsant
Rationale
Phenobarbital is a particularly important compound because of the availability of extensive human and animal experimental data. Phenobarbital is a classic prototype for a class of microsomal enzyme inducers that induce a similar spectrum of isozymes and is a widely studied hepatic tumor promoter. Phenobarbital also has tumor promoting activity in the thyroid gland. A number of carcinogenicity studies have been conducted with phenobarbital in mice and depending on the strain, hepatocellular adenomas, carcinomas and hepatoblastomas can be observed. Phenobarbital is considered to be generally nongenotoxic and to act via tumor promotion as a mode of action. In relatively extensive human epidemiologic studies with phenobarbital there is no evidence for an increased risk of liver cancer or cancer at any other site.
Rodent Carcinogenicity
Phenobarbital has been tested for carcinogenicity in rats and mice. In rat studies phenobarbital is either negative or produces hepatocellular adenomas. The response in mice varies depending upon the duration of treatment and the strain of mouse studied; however hepatocellular adenomas and carcinomas and hepatoblastomas have been observed. Phenobarbital has been shown to have hepatic tumor promoting activity in rats and mice but not in hamsters.
Genotoxocity
Numerous short term tests for genotoxicity have been conducted with phenobarbital. Although weak, equivocal or mixed results have been observed in some assays, phenobarbital is considered to be generally nongenotoxic. Phenobarbital is negative for DNA damage in liver speci c tests including alkaline elution, unscheduled DNA synthesis ([UDS], in-vivo and in-vitro), tests for DNA adducts, or mutations in the liver of transgenic mice.
Epidemiology
Relatively extensive human epidemiologic studies provide no evidence for an increased risk of liver cancer or cancer at any other site. A signi cant decrease in bladder cancer has been observed in phenobarbital treated epileptics. 
Reviews/Monographs
SULFAMETHOXAZOLE
Compound
Sulfamethoxazole (CAS # 723-46-6). The chemical name is N -(5-methylisoxazol-3-yl)sulphanilamide. Its molecular weight is 253.3. It is a white or yellowish white, odorless, crystalline powder. Practically insoluble in water but soluble in ethanol (1 in 50) and acetone (1 in 3) and aqueous alkaline hydroxides. The compound is available from Sigma Chemical Company Cat # S7507.
Pharmacologic Activity
Antibacterial agent
Rationale
Sulfamethoxazole is a widely used antibacterial agent for the treatment primarily of urinary tract infections. In combination with trimethoprim, it has been the most commonly used sulfonamide around the world and, in combination with pyrimethamine is used in the treatment of chloroquineresistant malaria. Administration of sulfamethoxazole to rats, mice, or dogs produces thyroid hyperplasia as a result of stimulation of release of thyroid stimulating hormone (TSH) but its goitrogenic effects do not appear to occur in monkeys.
Rodent Carcinogenicity
Swarm et al. (1) reported that in rats treated with 25, 50, 150, 300, or 600 mg/kg of sulfamethoxazole for 66 weeks, thyroid nodules or adenomas were observed respectively with the following incidence: 0/28, 7/30, 20/29, 19/27, and 23/23. Lung metastases were observed in 4 rats from the 3 higher dose groups. Sulfamethoxazole is absorbed rapidly with peak plasma level in mice after a 1 g/kg oral dose of 1.0 mg/ml at 1 hr after administration. Tissue distribution studies in rats showed high concentrations of sulfamethoxazole in kidney, lung, liver, spleen, and brain. Tissue elimination paralleled elimination from the blood (plasma elimination half-life 6 hr).
Genotoxicity
Sulfamethoxazole did not produce chromosome aberrations in vitro in human lymphocytes. In combination with trimethoprim, sulfamethoxazole also had no effect on chromatid breaks in human broblasts in vitro. In vivo administration of sulfamethoxazole in adults and children at therapeutic dose levels ( 2 gm/day) did not increase the frequency of chromosome aberrations in human lymphocytes.
Sulfamethoxazole has also been reported to not be mutagenic in bacteria.
Epidemiology
In a retrospective cohort study of 95 commonly used drugs tested for associations with primary cancers at different sites in which a number of nominally signi cant associations may have occurred by chance, 1,709 sulfamethoxazole users had statistically signi cant excesses noted for nasopharyngeal cancers (3 cases observed vs 0.1 expected) and cervical cancers (7 cases observed and 2.2 expected). The latter association may be explained by sexual activity which is related to both cervical cancer and to urinary tract infection for which sulfamethoxazole is prescribed. A signi cant de cit of colon cancer was also seen (none observed and 4.7 expected). There was no signi cant association with all cancers combined (42 observed vs 43.9 expected).
SULFISOXAZOLE
Compound
Sul soxazole (CAS 127-69-5, NCI C50022) is a derivative of sulfanilamide (1) . The chemical name is benzenesulfonamide, 4-amino-N-(3,4-dimethyl-5-isoxazolyl)-. The compound is a white to slightly yellowish crystalline powder with bitter taste. The molecular weight is 267.31 and the solubility in water is 0.13 mg/mL. It is soluble in alcohol. The compound is available from Spectrum Quality Products, Inc. (Gardena, CA).
Pharmacologic Activity
The compound is a broad spectrum antibacterial, primarily for urinary tract infections, but also for other bacterial infections.
Rationale
Sul soxazole was selected because of extensive clinical experience and the lack of carcinogenicity in rodent bioassays. Sul soxazole has been used extensively in humans since 1949. The maintenance oral dose for sul soxazole in humans in 4-8 g/day, divided into 4-6 doses. Sul soxazole appears not to possess the potential to induce thyroid tumors in rodents, as occurs with some other sulfanilamides.
Rodent Carcinogenicity
Rodent bioassays of sul soxazole were conducted by the National Cancer Institute (2) . In the NCI bioassays, sul soxazole was tested in Fischer 344 rats and B6C3F 1 mice. Both species were given daily gavage doses of sul soxazole for 2 years, 100 or 400 mg/kg for rats, and 500 or 2000 mg/kg for mice. Survival rates and tumor incidences were unaffected by treatment. Mean body weights of high-dose male rats and female mice were slightly lower than those of controls during the latter part of the study (speci c data not shown). It was concluded that the animals could probably have tolerated higher doses of the compound. No evidence of effects on the thyroid, as seen with a number of sulfanilamides, was present in these studies.
Genotoxicity
Sul soxazole was mutagenic in mouse lymphoma cells without metabolic activation in vitro (3) and induced sister chromatid exchange in Chinese hamster ovary cells in activated and nonactivated systems in vitro (4). The compound was not mutagenic in E coli or Salmonella (5) and did not induce chromosomal aberrations in Chinese hamster ovary cells in vitro (4), with or without metabolic activation in either system. Sul soxazole did not induce micronuclei in vivo (6) .
Epidemiology
In a hypothesis seeking study, no signi cant excess of any cancer was observed in 11,659 subjects who had received sul soxazole. The IARC evaluation is that the data are not suf cient for an evaluation of the carcinogenicity of sul soxazole to humans (7) .
Dose Justi cation for P53 Hemizygous Mouse Study With Sul soxazole
A pilot study was conducted in which C57BL/6, wild-type, mice received sul soxazole in the diet for 28 days. Mice, 5/sex/group, received 0%, 0.5%, 1%, 2%, or 4% sul soxazole in the diet, resulting in average daily intake of 0, 1.4, 2.8, 5.1, or 9.8 g/kg for males and 0, 1.1, 2.1, 4.7, or 7.3 g/kg for females.
During the rst 6 days of the treatment period, food consumption of the high-dose (4%) group mice was markedly reduced and males and females of this group lost approximately 21% and 15%, respectively, of their initial body weight. Three males and one female died or were killed moribund on day 6 or 7, and the remaining 4% group mice were terminated on day 7. Pathology ndings in these mice included thinness, emaciation, hemorrhages (gross and/or microscopic), myocardial degeneration, and hypertrophy of thyroid follicular epithelium. Changes in clinical pathology parameters were generally secondary to the hemorrhage and myocardial degeneration.
Changes in body weight and food consumption in mice treated for 28 days were limited to the 2% group. Mice of this group had 53% to 55% reduction of body weight gain, compared to controls, through day 9 for males and through day 13 for females, but no differences from controls during the remainder of treatment. Mean daily food consumption for females was less than that of controls during the latter 2 weeks of treatment, and EFU of females was less than that of controls during the second week.
There were no important changes in clinical pathology parameters in mice at the end of the one month treatment period. Minor increases (approximately 10% to 20%) in liver weights occurred in males of the 1% and 2% groups and females of the 2% group. Slight increases (approximately 16%-28%) in spleen weights also occurred in the 1% and 2% male groups. Treatment-related histologic ndings were limited to minimal-to-slight hypertrophy of thyroid follicular epithelium in 2 of 5 males of the 1% group and most males and females of the 2% group.
Plasma concentrations of sul soxazole were determined on samples collected at approximately 0800 hours on days 14 and 28. Three pooled plasma samples/sex/treatment/collection day were produced by pooling plasma from 3 mice for each sample. The plasma samples were analyzed by liquid chromatography/mass spectroscopy (LC/MS/MS). Plasma concentrations for males were 70 to 102, 89 to 114, and 105 to 116 l g/mL on day 14 and 68 to 75, 66 to 91, and 76 to 98 l g/mL on day 28 for the 0.5%, 1%, and 2% groups, respectively. Plasma concentrations for females were 51 to 69, 82 to 83, and 100 to 135 l g/mL on day 14 and 72 to 88, 70 to 85, and 79 to 91 l g/mL on day 28 for the 0.5%, 1%, and 2% groups, respectively.
Therapeutically effective blood levels of sulfonamides in humans are 50 to 150 l g/mL, and maximal levels should not exceed 200 l g/mL to avoid adverse effects. Average steady state blood levels of sul soxazole following 500 mg QID dosing are 49.9 to 88.8 l g/mL (8) .
Dietary concentrations of 0.05%, 0.5%, and 2% were selected for the 6 month study in C57BL/6 P53 hemizygous mice. Dietary administration should result in fairly constant systemic exposure. While these doses do not provide any multiples of human therapeutic exposure levels, the high dose of 2% is one-half the dose causing lethality in the pilot study. Continued administration of 2% is expected to result in minimal effects on food consumption and body weight, slight increases in liver weights, and possibly slight effects on thyroid follicular cell morphology. The 0.5% concentration is expected to be a no-effect dose and provide a bridge to results of the pilot study. The low dose, 0.05%, should provide an actual delivered dose similar to a human dose of about 100 mg/kg.
